No Data
No Data
No Data
Express News | Biohaven Ltd : Morgan Stanley Initiates Coverage With Overweight Rating; Target Price $58
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biohaven Ltd. (BHVN), HCA Healthcare (HCA) and Kiniksa Pharmaceuticals (KNSA)
Buy Rating Affirmed for Biohaven Ltd. Amidst Expansion and Progress in R&D Programs
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), BridgeBio Pharma (BBIO) and Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) Gets a Buy From RBC Capital
Optimistic Outlook: Buy Rating Affirmed for Biohaven Ltd. Amid Promising Pipeline and Synergistic Drug Potential
No Data